AI PRICE FORECAST
TMO Stock Forecast & AI Price Prediction
Thermo Fisher Scientific · Healthcare · Diagnostics & Research
TMO live signal snapshot
TMO last traded at $717.71, down 0.07% on the session, trading within 1.4% of its 52-week high of $727.56. Our AI model's current call on TMO is BUY, with 86% confidence. Short-term momentum is constructive: the 5-, 10- and 20-day moving averages are stacked upward and price is holding above the 50-day average. The model's one-month path points toward roughly $742.10 (3.4% from here).
On the 14-day relative strength index, TMO reads 63.4, showing buyers in control without the stretch of an overbought reading. Its MACD line is above its signal line with a positive histogram (1.11) — upward momentum is accelerating. Its 50-day average ($667.17) is holding 20.3% above the 200-day ($554.38), the pattern chartists call a golden cross.
The average 12-month target from 25 Wall Street analysts is $756.52 (range $590.00–$830.00) — 5.4% upside from where TMO trades now. The current recommendation trend leans bullish: 23 Buy/Strong Buy ratings vs 1 Sell/Strong Sell (and 3 Hold).
Live figures from real market data feeds, current as of the last site build. Open the interactive TMO dashboard for numbers updated throughout today's session.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. (TMO) is a diagnostics & research company in the healthcare sector, headquartered in Waltham, MA, United States. Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services internationally. It has a market value of about $265.9 billion and roughly 125,000 full-time employees. Its beta of 0.84 means it has historically moved roughly in line with the market.
TMO performance vs. the market
TMO is up 23.9% so far in 2026, ahead of the S&P 500 (+11.4%) and ahead of the healthcare sector fund XLV (+22.1%). On a one-year view it is up 24.5%, 13.0 points better than the S&P 500. The last month (+8.2%) continues the three-month advance (+20.4%).
| Period | TMO | Sector (XLV) | S&P 500 |
|---|---|---|---|
| 1 month | +8.2% | +11.4% | −2.3% |
| 3 months | +20.4% | +12.2% | −2.3% |
| Year to date | +23.9% | +22.1% | +11.4% |
| 1 year | +24.5% | +28.3% | +11.5% |
Thermo Fisher Scientific financials at a glance
In the quarter ended Sep 30, 2026, Thermo Fisher Scientific reported revenue of $12.1 billion and net income of $1.7 billion (a 14.2% net margin). Revenue was up 9.1% from the same quarter a year earlier. The stock trades at a price-to-earnings ratio of 37.9 on trailing earnings of $18.96 per share. Trailing free cash flow was $6.4 billion, and total debt equals 75% of shareholders' equity.
| Quarter ended | Revenue | Net income |
|---|---|---|
| Sep 30, 2026 | $12.1B | $1.7B |
| Jun 30, 2026 | $12.0B | $1.7B |
| Mar 31, 2026 | $11.0B | $1.7B |
| Dec 31, 2025 | $12.2B | $2.0B |
TMO vs. its peers
Against 5 of its largest healthcare peers, TMO's +23.9% year-to-date return beats 3 of them. The strongest of the group this year is Eli Lilly and (LLY, +33.7%).
| Company | Price | YTD | P/E | AI verdict |
|---|---|---|---|---|
| Thermo Fisher Scientific (TMO) | $717.71 | +23.9% | 37.9 | BUY |
| Danaher (DHR) | $235.31 | +2.8% | 39.0 | BUY |
| IDEXX Laboratories (IDXX) | $702.59 | +3.9% | 47.3 | BUY |
| Agilent Technologies (A) | $176.95 | +30.0% | 34.9 | BUY |
| IQVIA Holdings (IQV) | $274.53 | +21.8% | 33.4 | BUY |
| Eli Lilly and (LLY) | $1,437.29 | +33.7% | 46.7 | BUY |
TMO stock: common questions
What is the TMO stock price target?
25 Wall Street analysts put the average 12-month target at $756.52, in a range of $590.00–$830.00, versus a recent price of $717.71. Stock Pulse 247's model projects about $742.10 over the next month.
Is TMO a buy right now?
Our AI model currently rates TMO a BUY at 86% confidence. Among analysts, 23 rate it Buy or Strong Buy, 3 Hold and 1 Sell. Neither is personal advice — weigh them with your own research and risk tolerance.
How has TMO stock performed this year?
TMO is up 23.9% so far in 2026, ahead of the S&P 500 (+11.4%) and ahead of the healthcare sector fund XLV (+22.1%). On a one-year view it is up 24.5%, 13.0 points better than the S&P 500. The last month (+8.2%) continues the three-month advance (+20.4%).
What is TMO's 52-week high and low?
TMO has traded between $435.27 and $727.56 over the past 52 weeks; at $717.71 it is within 1.4% of its 52-week high of $727.56.
What sector is TMO in, and who are its peers?
TMO is in the healthcare sector (diagnostics & research). Its largest peers on Stock Pulse 247 include Danaher (DHR), IDEXX Laboratories (IDXX), Agilent Technologies (A), IQVIA Holdings (IQV).
How accurate is the TMO forecast?
It's a model estimate from price history, technical indicators and analyst targets, not a guarantee — no model predicts short-term moves reliably. Use it as one input alongside your own research.
How this works: the forecast combines TMO's price history, momentum indicators (RSI, MACD, moving averages), volatility and analyst targets into one estimate. It's a model, not a guarantee.